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ABSTRACT Transforming growth factor b (TGF-b) signaling, which regulates multiple cellular processes including proliferation,
apoptosis, and differentiation, plays an important but incompletely understood role in normal and cancerous tissues. For
instance, although TGF-b functions as a tumor suppressor in the premalignant stages of tumorigenesis, paradoxically, it also
seems to act as a tumor promoter in advanced cancer leading to metastasis. The mechanisms by which TGF-b elicits such
diverse responses during cancer progression are still not entirely clear. As a ﬁrst step toward understanding TGF-b signaling
quantitatively, we have developed a comprehensive, dynamic model of the canonical TGF-b pathway via Smad transcription
factors. By describing how an extracellular signal of the TGF-b ligand is sensed by receptors and transmitted into the nucleus
through intracellular Smad proteins, the model provides quantitative insight into how TGF-b-induced responses are modulated
and regulated. Subsequent model analysis shows that mechanisms associated with Smad activation by ligand-activated
receptor, nuclear complex formation among Smad proteins, and inactivation of ligand-activated Smad (e.g., degradation,
dephosphorylation) may be critical for regulating TGF-b-targeted functional responses. The model was also used to predict
dynamic characteristics of the Smad-mediated pathway in abnormal cells, from which we generated four testable hypotheses
regarding potential mechanisms by which TGF-b’s tumor-suppressive roles may appear to morph into tumor-promotion during
cancer progression.
Biophysical Journal Volume 96 March 2009 1733–1750 1733INTRODUCTION
Transforming growth factor-b (TGF-b) proteins are
members of a superfamily of secreted cytokines that control
a diverse array of cellular processes including cell prolifera-
tion, differentiation, motility, adhesion, angiogenesis,
apoptosis, and immune surveillance (1–3). The TGF-b
signaling cascade begins when activated TGF-b binds to
and brings together Type I and Type II TGF-b receptor
serine/threonine kinases on the cell surface, whereby the
Type II receptor phosphorylates and activates the Type I
receptor. The activated Type I receptor, in turn, propagates
the signal through phosphorylation of receptor-bound
(R-)Smad transcription factors (Smad2/3 and Smad1/5/8)
at the carboxy-terminal SXS motif. The activated R-Smads
form hetero-oligomers with a common partner or co-Smad,
namely Smad4, and rapidly translocate into the nucleus
where they undergo continuous nucleocytoplasmic shuttling
by interacting with the nuclear pore complex. Once in the
nucleus, activated Smad complexes bind to specific
promoters and ultimately regulate expression of target genes
through interactions with other transcriptional co-activators
and co-repressors, generating ~500 gene responses in
a cell- and context-specific manner (1,3–6).
The TGF-b signaling pathway has become an attractive
but difficult target for oncology drug development because
of its apparently paradoxical roles in tumorigenesis and
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0006-3495/09/03/1733/18 $2.00metastasis. In normal and early phase tumorigenic epithelial
cells, TGF-b functions as a potent tumor suppressor
primarily by inducing cell cycle arrest and apoptosis.
However, in the intermediate and late stages of carcinogen-
esis, tumor cells become resistant to the growth inhibitory
effects of TGF-b and show elevated expression of TGF-b.
The ligand is overexpressed in clinical cancer samples,
with increasing levels correlating with poor clinical
outcomes (7–9). The role of TGF-b therefore seems to
become one of tumor promotion, apparently supporting
growth, subverting the immune system, and also facilitating
angiogenesis, epithelial to mesenchymal transition (EMT),
and invasion. This finding has created the widely held
perception that TGF-b acts as a tumor promoter in advanced
tumorigenesis and metastasis (10–12). Although it is known
that most cancer cell lines representing the entire spectrum of
tumor progression have active TGF-b signaling pathways,
detailed mechanisms of how a single stimulus, TGF-b,
induces such a diverse array of responses during cancer
progression remains poorly understood.
One of the major obstacles to understanding TGF-b
biology is the complexity of the signaling cascade system
in which a variety of signaling components that change
dynamically over different time scales interact with one
another. Quantitative understanding and analysis of such
a complex regulatory circuit are not possible via qualitative
human intuition alone; mathematical descriptions that lead
to predictive models are necessary, and have become useful
in improving our understanding of this complex signaling
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understanding the biochemistry of the TGF-b pathway,
quantitative modeling of the TGF-b signaling system
remains in its infancy; several models have been published,
but each has focused on restricted portions of the pathway.
Vilar et al. (13) explored a model of TGF-b signal processing
at the receptor level. They modeled TGF-b receptor traf-
ficking events taking place concurrently at the plasma
membrane and in endosomes. They incorporated the
processes of receptor internalization into endosomes, recy-
cling to the plasma membrane, constitutive and ligand-
induced receptor degradation, and receptor protein synthesis
in their model. In contrast, Clarke et al. (14) focused on intra-
cellular signaling via the Smad-mediated pathway where
they incorporated several steps into both the cytoplasmic
and the nuclear events such as R-Smad phosphorylation
and dephosphorylation, and nucleocytoplasmic shuttling of
Smad proteins. However, this model does not show a direct
relationship between an extracellular TGF-b ligand and
intracellular responses because signaling is initiated by the
activated receptor complex, not by TGF-b ligand itself.
The dynamic behavior of the ligand-stimulated receptor
complex was described by a simple decreasing exponential
function.
Melke and coworkers (15) presented a minimalist model
of TGF-b signal transduction in endothelial cells for which
downstream signaling is effected via two Type I receptors
(ALK1 for Smad1/5/8 and ALK5 for Smad2/3). This model
used significantly simplified signaling mechanisms in the
pathway at both the surface and the intracellular levels,
and incorporated an inhibitory protein, Smad7, to implement
a simplistic feedback loop. A more recent contribution from
Zi and Klipp (16) offered more detailed receptor trafficking
than the Vilar model, and incorporated a simplified Smad-
pathway and ligand-induced receptor inhibition. The latest
model by Schmierer et al. (17) focused on Smad nucleocyto-
plasmic dynamics, providing a better description of the Smad
pathway than the earlier models; but this model still lacks
a detailed description of the dynamic process of receptor traf-
ficking and TGF-b-induced receptor activation.
Thus, although these previous modeling efforts have
provided adequate descriptions of various aspects of the
TGF-b signaling pathway, none provides a sufficiently
comprehensive and/or realistic description of the signaling
cascades, limiting their ability to facilitate understanding
and analysis of the complex TGF-b system and to predict
system behavior under aberrant conditions accurately. In
particular, the oversimplification or omission of some impor-
tant steps in the pathway used in these models limits their
suitability for use in attempting to unravel the mystery of
the seemingly contradictory roles of TGF-b in cancer
progression. Such applications require a more comprehen-
sive and more realistic description of the signaling pathway.
As a first step in understanding TGF-b signaling quantita-
tively, we present in this study, an integrated TGF-b pathway
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extracellular signal (i.e., the ligand-binding, receptor activa-
tion and trafficking), transmission of the signal (i.e., the
canonical downstream Smad pathway), and by modifying
and adding some important mechanisms (sequential receptor
activation, protein synthesis, constitutive and ligand-induced
degradation of signaling components, nuclear dephosphory-
lation of Smad, nuclear Smad complex formation, etc.), in
accordance with the most up-to-date information available
about the TGF-b signaling system. The result, as described
below, is a system of ordinary differential equations
(ODEs) from which, given as input the concentration of
the extracellular TGF-b ligand, one obtains as the primary
output of interest, namely the dynamic behavior of the
activated Smad2-Smad4 complex in the nucleus, which
ultimately determines target gene expression and cellular
responses, along with the dynamics of other intermediate
signaling component proteins. Through simulation and
model analysis, our model provides insight into the signal-
response relationship between the binding of TGF-b to its
receptor at the cell surface and the activation of downstream
effectors in the signaling cascade. In particular, we use the
model to carry out ‘‘in silico mutations’’ from which we
generate several hypotheses regarding potential mechanisms
for how TGF-bs tumor-suppressive roles may seem to morph
into tumor-promoting roles.
MATERIALS AND METHODS
Model development
The following is a description of the essential molecular processes on which
the model is based.
The binding of ligand to signaling receptors
TGF-b ligands activate signaling by binding to and bringing together pairs
of Type I and Type II receptors. Specifically, the active form of dimeric
TGF-b (assumed to be a single unit) binds to the ectodomain of dimeric
Type II receptor (TbRII, designated as RII in the kinetic scheme) and forms
a catalytically active TGF-b-RII complex (designated as TGFb-RII). The
activated TGFb-RII complex subsequently interacts with Type I receptor
(TbRI or ALK5, designated as RI), and activates it, forming a TGFb-RII-
RI complex (designated as RC) at the cell surface (1), which is ready for
downstream signaling.
Receptor internalization and recycling
It has been reported that TGF-b receptors are continuously internalized via
clathrin-coated pits into early endosomes and are recycled to the plasma
membrane for signaling, even in the absence of ligand (18,19). Vilar et al.
(13) have modeled the dynamic behavior of TGF-b receptors, considering
receptor internalization and recycling. We adopt the approach of Vilar and
coworkers, using first-order kinetics to describe receptor trafficking.
Smad phosphorylation
Although the receptors for TGF-b signal through both Smad2 and Smad3
proteins in epithelial cells, we select Smad2 to represent the R-Smads,
because the two are virtually identical kinetically; furthermore, Smad2 is
~12-fold more abundant than Smad3 (14,20). Based on previous studies
showing that Smad activation for signaling requires internalization of the
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first with the activated ligand-receptor complexes internalized into early
endosomes, and then is phosphorylated.
Smad heteromerization
The stoichiometry of active R-Smad/Smad4 heteromeric complexes remains
a controversial topic; the R-Smad/Smad4 complexes have been suggested to
function as either dimers or trimers after homodimerization of R-Smad
(23–28). For simplicity, we assume that phosphorylated Smad2 and
Smad4 form a heterodimeric complex. In principle, receptor-activated
R-Smads, after undergoing a conformational change to allow for association
with other activated Smads, could associate with either another R-Smad and/
or Smad4 in the cytoplasm first, followed by their entry into the nucleus as
RSmad-Smad4 complexes; alternatively, these complexes could form after
R-Smads translocate into the nucleus (29,30). The latter implies nuclear
import of monomeric or dimeric phosphorylated R-Smads, which is dis-
cussed next.
Nucleocytoplasmic shuttling
In the basal state, both R-Smads and Smad4 are predominantly localized in
the cytoplasm. However, on ligand stimulation, both species rapidly accu-
mulate in the nucleus (30,31). It is becoming clear that these distributions
are not static; rather both R-Smads and Smad4 shuttle continuously between
the cytoplasm and nucleus regardless of TGF-b stimulation, ultimately
reaching a dynamic equilibrium (20,32–34). We therefore consider both
import and export steps for monomeric R-Smad and Smad4 in our model.
Although it is widely believed that activated R-Smads translocate into the
nucleus in the heteromeric complex form with Smad4, it has been observed
that complex formation of TGF-b-induced R-Smads with Smad4 is not
always necessary for their accumulation in the nucleus (30,35,36). We there-
fore include nuclear import of receptor-phosphorylated R-Smad monomers
in the cytoplasm in the model.
It has been suggested that the nuclear export signal of Smad4 may be
masked through complex formation with activated R-Smads (3,20,30),
resulting in nuclear accumulation of Smad4 after TGF-b stimulation.
Also, a recent study proposed that only monomeric unphosphorylated
Smad2 is capable of export so that the phosphorylated complex form of
Smad2 is trapped in the nucleus (32). These observations provide the basis
for our assumption that translocation of activated monomeric R-Smads and
heteromeric RSmad-Smad4 complex is unidirectional.
Developing realistic mathematical descriptions of nucleocytoplasmic
shuttling of Smads has been complicated by the complexity of, and uncer-
tainty associated with, the import and export mechanisms that depend
on the type of R-Smads. For example, regarding nuclear import, it has
been proposed that Smad2, Smad3, and Smad4 enter the nucleus by direct
interactions with the nuclear pore complex (37,38). However, it also has
been suggested that the nuclear import of Smad3 and Smad4 depends on
the nuclear import factor, importin-b (39,40). On the other hand, Smad4
export from the nucleus is mediated by CRM-1 (chromosomal region main-
tenance-1) nuclear export factor, whereas R-Smad export is independent of
CRM-1 and simply may be mediated by direct interactions with nucleopor-
ins (37,38). In the absence of a consensus, we opt for a simple mechanism of
nucleocytoplasmic shuttling, assuming first-order kinetics for both import
and export steps.
Dissociation and dephosphorylation
Suspecting the existence of unidentified R-Smad phosphatases, it has been
proposed that R-Smads should undergo cycles of phosphorylation and
dephosphorylation to shuttle between the cytoplasm and the nucleus in the
presence of a TGF-b signal (20,30,32,34). Lin et al. (41) confirmed this
postulate about the existence of the phosphatases by identifying a Smad-
specific phosphatase, PPM1A, that directly dephosphorylates Smad2 and
Smad3 to limit their activation. Thus, it is believed that dephosphorylation
of Smad2 by PPM1A or other phosphatase leads to dissociation ofR-Smad-Smad4 complexes to terminate the TGF-b signaling on receptor
deactivation, or to recycle R-Smads in the presence of a prolonged TGF-b
signal, implying that dephosphorylation precedes dissociation. However,
because a receptor-phosphorylated R-Smad monomer also may form
a complex with Smad4 after R-Smads translocate into the nucleus as well
as in the cytoplasm, we cannot rule out the possibility of activated Smad
complex dissociation before dephosphorylation (42). We therefore include
both steps in our model. It has been reported that PPM1A is primarily local-
ized in the nucleus regardless of TGF-b stimulation (41), which supports the
previous suggestions that R-Smad dephosphorylation seems to occur in the
nucleus (29,34). This leads us to take only nuclear dephosphorylation into
account in our model.
Protein degradation
Each signaling component in the pathway is irreversibly eliminated via
different mechanisms. First, degradation of receptors can occur via two
different modes: ligand-dependent degradation targeted by Smad7-Smurf2
via the lipid-raft caveolar pathway, and ligand-independent (or constitutive)
degradation (13,19). We assume that ligand-unbound Type I and Type II
receptors, and ligand-induced receptor complexes at the surface are termi-
nated in the pathway, as suggested by Vilar et al. (13). Second, it has
been reported that receptor-activated Smad2 undergoes TGF-b-induced,
ubiquitin-dependent degradation (43). It also has been suggested that protea-
somal degradation of Smad2 is likely to occur in the nucleus, mediated by
the interaction of Smurf2 with phosphorylated Smad2 (44), whereas Smurf2
is known as a cytoplasmic protein (45). Thus, it remains unclear whether
Smad2 is targeted to either nuclear or cytoplasmic proteasomes or both. In
this study, we assume that monomeric receptor-phosphorylated Smad2 is
irreversibly removed by nuclear proteasomes, and un- and/or dephosphory-
lated single Smad2 is eliminated in the cytoplasm. Last, it has been reported
that ubiquitination and proteasomal degradation of Smad4 is mediated by its
direct interaction with Jab1, known as a coactivator of c-Jun and subunit
of COP9 signalosome (46). We assume that Smad4 is eliminated in the
cytoplasm.
Protein synthesis
Describing the production of proteins in a mathematical manner is quite
complicated because of the uncertainty and complexity of the nuclear mech-
anisms for gene expression. Alternatively, many mathematical models of
cell signaling that deal with proteins alone assume constant production of
the signaling components (13,15,47). Likewise we also assume that the
4 major signaling components (i.e., Type I and Type II receptors, Smad2,
and Smad4) are produced under stationary conditions regardless of the pres-
ence of ligand.
The components of the overall TGF-b signaling pathway as featured in
our model are depicted in Fig. 1. The resulting model is a system of 17
nonlinear ODEs with 37 kinetic parameters arising from chemical reactions
represented by mass action kinetics. The complete set of model equations,
shown in Table 1, is integrated using the ODE15s routine of MATLAB
7.1 (The MathWorks, Natick, MA).
Our model is based on three well-mixed compartments with the basic
cellular characteristics defined for human keratinocyte HaCaT cells as
follows: the extracellular (calculated as 1 mL/106 cells), the cytoplasmic,
and the nuclear compartments. The cell is idealized as a sphere with a diam-
eter of 15 mm, resulting in a cell volume of 1.5  1012 L. Because, accord-
ing to Schmierer and Hill (32), an average cytoplasmic/nuclear volume ratio
for HaCaT cells is ~3, we choose the values 1.13  1012 L and 3.75 
1013 L, respectively, for the volumes of the cytoplasmic and nuclear
compartments.
Initial conditions
We select the value 10,000 for the total number of TGF-b receptor molecules
in the basal state. (This number is the median of the values presented in the
literature (48)). Assuming that Type I and Type II receptors are distributed
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1736 Chung et al.FIGURE 1 Schematic representation of the pathway components in the integrated model. Numbers in the cartoon refer to the chemical reaction indices in
Table 1.evenly, we choose the value 5,000 each for the initial number of Type I and
Type II receptor molecules. From recent observations that receptors are
internalized continuously and recycled to the surface whether ligand is
present or not, we assume that only 10% of total receptors are present inthe plasma membrane at any one time and that the remaining 90% of total
receptors are sequestered in endosomes (13,18,19). We also selected
100,000 to represent the total number of each Smad effector, in our case,
Smad2 and Smad4 molecules (14). In the basal state, 15% of total Smad2TABLE 1 Model equations
v1 ¼ k1a½TGFb ½RII k1d½TGFb : RII v2 ¼ k2a½TGFb : RII ½RI k2d½RC

v3 ¼ k3int½RC v4 ¼ k4a½RCin ½S2cyt k4d½RCin : S2cyt

v5 ¼ k5cat½RCin : S2cyt v6 ¼ k6a½pS2cyt ½S4cyt k6d½pS2S4cyt

v7 ¼ k7imp½pS2S4cyt v8 ¼ k8dp½pS2S4nuc
v9 ¼ k9d½S2S4nuc v10 ¼ k10imp½S2cyt k10exp½S2nuc

v11 ¼ k11imp½S4cyt k11exp½S4nuc

v12 ¼ k12syn  k12deg½RII
v13 ¼ k13syn  k13deg½RI v14 ¼ k14syn  k14deg½S2cyt
v15 ¼ k15syn  k15deg½S4cyt v16 ¼ ðk16deg þ k16lidÞ½RC
v17 ¼ k17imp½pS2cyt v18 ¼ k18a½pS2nuc ½S4nuc k18d½pS2S4nuc
v19 ¼ k19dp½pS2nuc v20 ¼ k20lid½pS2nuc
n21 ¼ k21int½RII k21rec½RIIin n22 ¼ k22int½RI k22rec½RIin
n23 ¼ k23rec½RCin
d½RII
dt ¼ v1 þ v12  v21 þ v23 d½TGFb:RIIdt ¼ v1  v2 d½RIdt ¼ v2 þ v13  v22 þ v23
d½RC 
dt ¼ v2  v3  v16
d½RCin 
dt ¼ v3  v4 þ v5  v23
d½RCin:S2cyt 
dt ¼ v4  v5
d½S2cyt 
dt ¼ v4  v10 þ v14 d½pS2cyt dt ¼ v5  v6  v17 d½pS2S4cyt dt ¼ v6  v7
d½pS2S4nuc 
dt ¼ v7  v8 þ v18 d½S2S4nuc dt ¼ v8  v9 d½S2nucdt ¼ v9 þ v10 þ v19
d½S4nuc 
dt ¼ v9 þ v11  v18 d½S4cyt dt ¼ v6  v11 þ v15 d½pS2nuc dt ¼ v17  v18  v19  v20
d½RIIin 
dt ¼ v21 d½RIin dt ¼ v22
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Modeling of TGF-b Signaling 1737and 13% of total Smad4 are assumed to reside in the nucleus (32). All other
species are set to zero initially.
Model parameter estimation
To carry out simulations with the model requires specific values for the reac-
tion kinetic parameters. Parameter estimation, the procedure for determining
from a set of experimental data the values of unknown model parameters,
continues to receive attention in systems biology. However, currently there
is no consensus as to how to deal with such important related issues as
parameter identifiability, the possibility of multiple local minima, and high
computational costs. The approach taken in this study is summarized below.
Initial rough estimation
Several kinetic parameter values were determined through an extensive liter-
ature search; some were computed using available in vitro experimental
data; we also used physical constraints to determine others. For instance,
the dissociation constant Kd ¼ koff/kon is available for protein-protein
binding reactions, whereas the separate on- and off-rates, kon and koff, are
not. Under these conditions, we chose an initial estimate for kon by compar-
ison with similar steps in other kinase pathways and computed the corre-
sponding koff as koff ¼ Kd  kon. The remaining unknown parameters
were provided with initial estimates and reasonable upper and lower bounds
by comparison with similar circumstances in the literature (e.g., similar steps
in previous models or other signaling pathway models) and from known
physical limitations (e.g., the diffusion-limited rates, 108–109 M1 s1 (49)).
Parametric sensitivity analysis
To identify which parameters are the most important and which must there-
fore be estimated most precisely, using the set of initial estimates determined
in Step 1 above, we carried out local parameter sensitivity analysis to deter-
mine the effect of parametric changes on the set of five system responses of
interest for which experimental measurements are available (i.e., total
Smad2 in the nucleus and the cytoplasm (30), total phosphorylated Smad2
in the nucleus and the cytoplasm (20,30), and total Smad4 in the nucleus
(30)). The computations are based on the following expression for the
normalized sensitivity coefficient:
NSCijðtÞ ¼ pj
yi
vyiðt;pÞ
vpj

p
; i ¼ 1; 2;.; 5; j ¼ 1;.; 37;
where y and p respectively denote the system response variables and kinetic
parameters. A total of 13 parameters were selected to be estimated more
precisely because of their high sensitivity coefficients and/or because we
had little or no confidence in their initial values.
Least squares ﬁtting to data
We fit our model predictions simultaneously to corresponding in vitro exper-
imental data from the literature, via local minimization of the sum of squared
residual errors:
min
i
RðpÞ ¼ 1
2
X
yiðt;pÞ  yi ðtÞÞ2;
where yi(t,p) and yi*(t) denote, respectively, model predictions for a given
trial of parameter values, p, and the corresponding experimental measure-
ments, for each measured variable, i. The experimental data used for the
curve-fitting are time courses of i), total Smad2 in the nucleus (30); ii), total
Smad2 in the cytoplasm (30); iii), total phosphorylated Smad2 in the nucleus
(20); iv), total phosphorylated Smad2 in the cytoplasm (30); and v), total
Smad4 in the nucleus (30). We quantified the immunoblot literature data
with the Image Processing Toolbox in MATLAB 7.1, and normalized
both the experimental data and the corresponding model estimates to the
largest intensity point of each data set. The optimum parameter values (con-
strained to lie within the specified upper and lower bounds) were determined
using the nonlinear least square ‘‘lsqnonlin’’ routine of MATLAB 7.1.Identiﬁability
We carried out a ‘‘practical identifiability’’ analysis to determine whether the
unknown parameters of the postulated model can be estimated uniquely
from the available data, following Birtwistle et al. (50). Briefly, approximate
local confidence intervals (CI) for the parameter set are given by,
CIi ¼ tNtNpa=2
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
S
Nt  Np
s ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðZTZÞ1ii
q
;
where Nt and Np respectively denote the number of experimental data time
points and the number of parameters to be estimated; t
NtNp
a=2 is the Student’s
t-distribution statistic evaluated with Nt –Np degrees of freedom, at confi-
dence level 100(1 a)%, (with a as the ‘‘tail area probability’’ typically
set at 0.05 to yield a 95% confidence level); S is the sum of squared errors,
and Z is the model sensitivity matrix evaluated at the current parameter
values. The ith parameter is said to be practically locally identifiable only
if the magnitude of its approximate CI is less than a specified tolerance
i.e., jCIij< 3i. We chose tolerances such that the approximate CIs on identifi-
able parameters were set generously at ~40%.
Identiﬁable parameter estimate reﬁnement
Estimated values for identifiable parameters were refined further by
repeating Step 4 (local identifiability test) followed by Step 3 (local least
squares estimation). After obtaining the ‘‘best’’ estimates of this subset of
parameters, we carried out a final least squares estimation of the entire
parameter set.
The results of this procedure (final estimates as well as the identifiability
status of each parameter) are listed in Table 2.
RESULTS AND DISCUSSION
Model development and validation
Model ﬁt to literature data
A comparison of the model fit to the five sets of in vitro
experimental data used for parameter estimation is shown
in Fig. 2 A–E. First, Fig. 2 A shows the model fit to data
on total nuclear pSmad2 reported by Inman et al. (20) in
response to a step input of 2 ng/ml of TGF-b. Note the
good agreement between the model prediction and the
data. Furthermore, this dynamic profile also agrees well
with other reported experimental results that show the level
of nuclear pSmad2 peaking ~45–60 min after TGF-b treat-
ment and declining thereafter, but not to zero, even after
6–8 h (30,51). The model fit to total cytoplasmic pSmad2
data under conditions where protein synthesis is strongly
inhibited in the cells, as reported in Pierreux et al. (30), is
shown in Fig. 2 B. The model shows that the level of cyto-
plasmic pSmad2 drops sharply after peaking rapidly, and
remains very low thereafter. Considering that receptor-
activated Smad2 resides either in the cytoplasmic or in the
nuclear compartment, it appears as if more of pSmad2 accu-
mulates in the nucleus during active signaling of TGF-b
(20,32–34) than elsewhere.
Next, Fig. 2, C and D, show the model fit to experimental
profiles of total Smad2 in the nucleus and the cytoplasm,
respectively, under the conditions where cells were treated
continuously with 2 ng/mL of TGF-b and 20 mg of the
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Parameter Reaction step Value Unit Identifiability Reference
k1a Ligand binding 6.60 E  03 mol1 $ min1 Unidentifiable Estimation
k1d Dissociation 2.98 E  01 min1 N/a (66)
k2a Association (RI-RII*) 6.60 E  03 mol1 $ min1 Unidentifiable Estimation
k2d Dissociation 2.98 E  01 min1 N/a (67)
k3int Internalization (R
c) 3.95 E  01 min1 Unidentifiable Estimation (13),
k4a Association (R
c-S2) 1.50 E  04 mol1 $ min1 Unidentifiable Estimation
k4d Dissociation 9.71 E  01 min1 Unidentifiable Estimation
k5cat Turnover (pS2) 4.48 E þ 04 min1 N/A (68)
k6a Association (pS2-S4) 6.00 E  03 mol1 $ min1 Unidentifiable Estimation
k6d Dissociation 1.46 E þ 03 min1 N/A (23)
k7imp Nuclear import (pS2S4) 8.10 E  01 min1 Unidentifiable Estimation
k8dp Dephosphorylation (pS2S4) 2.52 E  02 min1 N/A Calculation (41)
k9d Dissociation (S2-S4) 1.01 E  01 min1 Unidentifiable Estimation
k10imp Nuclear import (S2) 1.62 E  01 min1 N/A (32)
k10exp Nuclear export (S2) 3.48 E  01 min1 N/A (32)
k11imp Nuclear import (S4) 2.01 E  02 min1 Unidentifiable Estimation
k11exp Nuclear export (S4) 1.74 E  01 min1 N/A (32)
k12syn Protein synthesis (RII) 8.00 E þ 00 mol $ min1 $ cell1 N/A Calculation
k12deg Degradation (RII) 2.80 E  02 min1 N/A (13)
k13syn Protein synthesis (RI) 8.00 E þ 00 mol $ min1 $ cell1 N/A Calculation
k13deg Degradation (RI) 2.80 E  02 min1 N/A (13)
k14syn Protein synthesis (S2) 2.74 E þ 01 mol $ min1 $ cell1 N/A Calculation
k14deg Degradation (S2) 6.46 E  04 min1 N/A Calculation (43)
k15syn Protein synthesis (S4) 5.00 E þ 01 mol $ min1 $ cell1 N/A Calculation
k15deg Degradation (S4) 1.20 E  03 min1 N/A Calculation (46)
k16deg Constitutive deg (R
c) 2.80 E  02 min1 N/A (13)
k16lid Ligand-induced deg (R
c) 3.95 E  01 min1 N/A (13)
k17imp Nuclear import (pS2) 5.03 E  01 min1 Identifiable Estimation
k18a Association (pS2-S4) 1.67 E  04 mol1 $ min1 Unidentifiable Estimation
k18d Dissociation 9.09 E  01 min1 Unidentifiable Estimation
k19dp Dephosphorylation (pS2) 2.52 E  02 min1 N/A As k8dp
k20lid Ligand-induced deg (pS2) 5.40 E  03 min1 Identifiable Estimation (41)
k21int Internalization (RII) 3.95 E  01 min1 N/A As k3int
k21rec Recycling (RII) 3.95 E  02 min1 N/A Calculation (13)
k22int Internalization (RI) 3.95 E  01 min1 N/A As k3int
k22rec Recycling (RI) 3.95 E  02 min1 N/A As k21rec
k23rec Recycling (R
c) 3.95 E  02 min1 N/A As k3int
RI, Type I receptor; RII, Type II receptor; RII*, phosphorylated Type II receptor; Rc, receptor complex; S2, Smad2; S4, Smad4; pS2, phosphorylated Smad2;
pS2S4, phosphorylated Smad2-Smad4 complex.protein synthesis inhibitor, cycloheximide (30). The concen-
tration of TGF-b represents a saturating concentration of this
factor expected to maximize signaling parameters. Note how
the dynamic pattern of the nuclear Smad2 response appears
to be the opposite of the cytoplasmic response. In other
words, although the level of nuclear Smad2 reaches a peak
and decreases thereafter, the amount of cytoplasmic Smad2
drops correspondingly and then increases. These opposite
dynamics may be caused by the shuttling of Smad2 between
the cytoplasm and the nucleus via a mechanism that involves
the steps of nuclear import and export of Smads; association
between nuclear pSmad2 and Smad4; dissociation of the
complex; and dephosphorylation of the activated Smad2,
and (re)phosphorylation of Smad2 by active receptors.
Finally, Fig. 2 E shows the model fit to experimental data
from Pierreux et al. (30) for total nuclear Smad4 in response
to a step of 2 ng/mL of TGF-b. Although Smad4 shuttles
continuously between the cytoplasm and the nucleus in the
absence of ligand, TGF-b stimulation allows Smad4 to reside
Biophysical Journal 96(5) 1733–1750more in the nucleus than in the cytoplasm through complex
formation with pSmad2. However, nuclear events such as
dephosphorylation of pSmad and dissociation of Smad
complex allow nuclear Smad4 to return to the cytoplasm.
Thus, nuclear Smad4 reaches peak activity at ~0.5–2 h after
ligand addition and declines thereafter (30).
Keeping in mind that the model was fit to these five data sets
simultaneously, the resulting agreement between model
prediction and data is quite good overall. The inevitable
discrepancies between model prediction and experimental
data are attributable to the following factors. First, the data
sets are from different laboratories and were therefore
acquired under nonidentical conditions (e.g., cell culture
conditions, cell population, batches of TGF-b, etc.). Thus,
model parameters that may be appropriate for one set of exper-
imental data may not be entirely appropriate for another. The
optimum model parameters will therefore result from
compromises whereby an otherwise ‘‘better’’ fit to a single
data set is traded off for a reasonable fit to the complete
Modeling of TGF-b Signaling 1739FIGURE 2 Model fit to experimental data: (A) total phosphorylated Smad2 in the nucleus (20), (B) total phosphorylated Smad2 in the cytoplasm (30), (C)
total nuclear Smad2 (30), (D) total cytoplasmic Smad2 (30), and (E) total nuclear Smad4 (30) in response to TGF-b stimulation. Note: to simulate the effects of
cycloheximide in (B–E), all rates of protein synthesis (k12syn, k13syn, k14syn, and k15syn) were set to zero.collection. Next, values for kinetic parameters (e.g., dissocia-
tion constants, Michaelis constants, etc.) determined from
in vitro measurements reported in the literature and used in
the model may not exactly correspond to values that obtain
under in vivo experimental conditions. Finally, to a lesser
extent, the model nonlinearity and constraints raise the
distinct possibility that the resulting optimum parameter set
may have been found in a local minimum. It is possible to
address this problem by using such global optimization
methods as genetic algorithm and simulated annealing, but
we do not believe that locating parameter estimates in local
minima is a sufficiently serious possibility for this specific
model to warrant the use of these techniques. Taking all of
these considerations into account, the model does a reasonable
job of capturing the dynamic behavior of TGF-b signaling as
reported in the experimental literature.
Model validation
Because the data sets shown in Fig. 2 A–E were used to
determine unknown model parameters by minimizing the
sum of squared differences between model prediction and
data, it is important, before proceeding to use the model,
to validate its prediction against a different set of indepen-
dent experimental data, without adjusting any model
parameters. To validate our model in this manner, we
compared its predictions to four independent experimental
data sets obtained from the literature: i), total phosphory-
lated Smad2 in the cell (43); ii), ratio of cellular pSmad2
to total Smad2 in response a step input in the ligand
concentration; iii), same as in (ii) except in response toa rectangular pulse input (41); and iv), total Smad4 in the
cytoplasm (30).
Fig. 3 A shows the predicted dynamics of total cellular
(cytoplasmic þ nuclear) Smad2 phosphorylation in response
to a step input of 200 pM of TGF-b, compared to the corre-
sponding experimental observations reported in Lo and
Massague (43). The model prediction, especially the early
response, shows remarkably good agreement with the data,
even though its deviation from data becomes somewhat
more pronounced with time after the peak.
A model prediction of the ratio of pSmad level to total
Smad in response to a step input of 2 ng/ml of TGF-b is shown
in Fig. 3 B compared to the experimental data of Lin et al.
(41). Again, the agreement between model prediction and
data is very good, with the prediction falling within the exper-
imental error bars. How the ratio of pSmad2 level to total
Smad2 responds to a short rectangular pulse of 2 ng/ml of
TGF-b followed by TbRI kinase inhibitor SB431542 to block
further phosphorylation (41) is shown in Fig. 3 C, where the
model prediction is seen to match the data almost perfectly.
Finally, for cells induced by a step input of 2 ng/ml of
TGF-b and treated by 20 mg of protein synthesis inhibitor,
cycloheximide (30), Fig 3 D shows the agreement between
the model prediction of cytoplasmic Smad4 response and
the experimental data.
Overall, given that these are results of direct model predic-
tions of four separate and independent experimental data
sets, with no model parameter adjustments, we conclude
that the model represents the dynamic behavior of the
TGF-b signaling pathway quite well.
Biophysical Journal 96(5) 1733–1750
1740 Chung et al.FIGURE 3 Model validation: (A)
total cellular pSamd2 (43); (B) ratio of
cellular pSmad2 to total Smad2 in
response to the step input of TGF-
b (41); (C) ratio of cellular pSmad2 to
total Smad2 in response to the pulse
input of TGF-b (41); (D) total cyto-
plasmic Smad4 (30). To simulate the
effects of cycloheximide in (D), all rates
of protein synthesis (k12syn, k13syn,
k14syn, and k15syn) were set to zero.Model analysis and simulation
In this section, we present results of computational ‘‘experi-
ments’’ used to explore the dynamic behavior of the now-
validated TGF-b signaling model. From among several
signaling components in the pathway, we select phosphory-
lated Smad complex in the nucleus to represent the signaling
activity of the TGF-b pathway because the expression of
TGF-b-inducible genes is regulated by nuclear activated
Smads. The premise is that such computational investiga-
tions into the dynamics of the TGF-b-induced Smad
complex in the nucleus, under various conditions, will facil-
itate understanding and characterization of the TGF-b/Smad
pathway; it also will provide clues regarding the role(s) of
this pathway in tumor progression and metastasis. All simu-
lations were carried out with the parameter values in Table 2,
and step inputs of 80 pM of TGF-b, unless otherwise
specified.
Model parameter sensitivity analysis
Although parameter sensitivity analysis has been shown to
play an important role in parameter estimation, it also can
be used to obtain insight into the model behavior itself.
Specifically, sensitivity analysis carried out for the primary
output of interest, nuclear pSmad2-Smad4 complex, will
help us understand quantitatively which aspects of the
pathway most affect the system behavior.
Fig. 4 shows normalized sensitivity coefficients as
a function of time for the 10 most important parameters
(parameters for which the maximum normalized sensitivity
Biophysical Journal 96(5) 1733–1750coefficient exceeds 0.5 in absolute value at any point in
time). The most important features of this plot are summa-
rized as follows: i), immediately after ligand stimulation,
the output variable is strongly affected by four of this set
of most sensitive parameters: in order of importance, these
are k4a (binding of Smad2 to active receptors), k3int (internal-
ization of receptor complexes), k7imp (nuclear import of
pSmad2-Smad4), and k2a (complex formation of activated
TbRII and TbRI); and ii), on the other hand, in the mid- to
FIGURE 4 Model parameter sensitivities for select parameters with the
greatest influence on phosphorylated Smad2-Smad4 complex in the nucleus.
Parameters with maximum normalized sensitivity coefficients exceeding 0.5
in absolute value at any point in time are shown.
Modeling of TGF-b Signaling 1741longer time interval after ligand stimulation, the following
parameters become more important: in order of importance,
these are k18a (association of nuclear pSmad2 and Smad4),
and k18d (dissociation of nuclear pSmad2-Smad4), k11exp
(nuclear export of Smad4), k20lid (ligand-induced degrada-
tion of pSmad2), k11imp (nuclear import of Smad4), k23rec
(recycling of internalized receptor complexes), k3int (inter-
nalization of receptor complexes), and k4a (binding of
Smad2 to active receptors).
These results have biologically important consequences.
First, the high sensitivity coefficients of the receptor-related
parameters (i.e., k2a, k3int, k4a, and k23rec) show that the
system responses to TGF-b are highly dependent on the
active state of the receptors. In particular, Fig. 4 shows that
45–60 min after TGF-b treatment, by which time nuclear
pSmad2-Smad4 would have reached its peak activity
(Fig. 2 A), the importance of the state of ligand-activated
receptors on the species again increases. Considering that
nuclear pSmad2-Smad4 complex loses its activity by
dephosphorylation and is destroyed by proteasomal degrada-
tion, this result implies that to maintain accumulation of
activated Smad complex in the nucleus, R-Smad must be
continuously phosphorylated by active receptors. Taking
into account that after ligand stimulation, free Smads in the
cytoplasm are either still unphosphorylated or have been ex-
ported from the nucleus after undergoing dephosphorylation,
this result reveals that the mechanism involving rephosphor-
ylation of Smad plays a vital role in the nuclear accumulation
of pSmad2-Smad4, especially at post peak times. To recycle
Smad2 for rephosphorylation during active signaling,
nuclear pSmad2 (either monomeric or heteromeric) must
undergo dephosphorylation by phosphatases because only
monomeric unphosphorylated Smad2 is capable of export
from the nucleus to the cytoplasm so that the phosphorylated
complexed form of Smad2 is trapped in the nucleus (32).
Although the sensitivity analysis shows that nuclear pSmad2
complex is less sensitive to changes in the dephosphorylation
step, this step is indispensable to the recycling of Smad2. To
conclude, the parametric sensitivity analysis shows that the
mechanisms for Smad2 recycling (i.e., phosphorylation-
dephosphorylation-rephosphorylation) have a critical effect
on the transcriptional activity of the signaling pathway.
The increasing nature of the sensitivity coefficients of k18a
and k18d over time shows that both the formation of pSmad2-
Smad4 complex in the nucleus and its dissolution are crucial
for nuclear retention of these complexes. Our model has two
sources of monomeric pSmad2 in the nucleus. One source is
the dissociation of pSmad2-Smad4 complexes that are
formed in the cytoplasm and then translocated to the nucleus;
the other is nuclear entry of monomeric Smad2 that was
phosphorylated in the cytoplasm. The former requires effec-
tive nuclear translocation of pSmad2-Smad4 complexes, as
confirmed by the high sensitivity coefficient of the parameter
k7imp. Unlike other parameters, however, the effect of the
nuclear import of activated Smad complexes is not signifi-cant over longer periods. On the other hand, considering
that the importance of k18a and k18d increases over time
(Fig. 4), it is likely that the latter source, the nuclear import
of cytoplasmic monomeric pSmad2, also plays a vital role in
the nuclear retention of pSmad2-Smad4 complexes. To
confirm this, we computationally ‘‘blocked’’ the nuclear
import of pSmad2-Smad4 complexes while allowing import
of pSmad2 monomer, and then prevented nuclear import of
pSmad2 monomer while allowing import of the complexed
pSmad to study the effects of these ‘‘blockades’’ on the
nuclear accumulation of active Smad complexes. Fig. 5
shows that the effect of blocking the nuclear import of cyto-
plasmic pSmad2-Smad4 complexes (i.e., the effect of
nuclear complex formation between pSmad2 and Smad4)
on nuclear retention of active Smad complexes is not trivial
compared to the effect of preventing the nuclear entry of
monomeric pSmad2. Taking the importance of Smad4 for
nuclear complex formation into account, it is not surprising
that the significance of nucleocytoplasmic shuttling of
Smad4 (k11imp and k11exp) increases at longer times. Many
biological ‘‘models’’ of the pathway mechanisms have
neglected the nuclear entry of monomeric pSmads and the
nuclear complex formation between Smad2 and Smad4,
but this result argues strongly for their incorporation.
The effect of Smad phosphorylation
As seen in previous sections, the nuclear accumulation of
Smad2-Smad4 complexes is significantly affected by the
dynamics of activated receptor complexes. To examine
how variations in the active state of receptors influence the
nuclear retention of pSmad2 complexes, we varied the rate
of the binding between ligand-activated receptor complexes
and Smad2 in the cytoplasm (k4a) 10-fold, because the
dynamics of the activated receptor complexes are ultimately
reflected in the phosphorylation of Smad2 for downstream
FIGURE 5 The effect of blocking translocation of monomeric pSmad2
(dashed, k17imp ¼ 0) or heteromeric pSmad2 (dash dot, k7imp ¼ 0).
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1742 Chung et al.FIGURE 6 The effect of variations in the rate of (A) Smad2 phosphorylation, (B) nuclear pSmad2-Smad4 association, (C) pSmad2 degradation, (D) nuclear
pSmad2 dephosphorylation, (E) and nuclear import of pSmad2 on the dynamics of nuclear pSmad2-Smad4 complex. Each indicated parameter value was
increased (dashed) or decreased (dash dot) 10-fold.signaling. Because it has been reported that Smad7, one of
the inhibitory Smads, can bind to activated receptors in
competition with R-Smads (29,52,53), this simulation may
also provide insight into the inhibitory effect of Smad7 on
TGF-b signaling. Fig. 6 A shows that when complex forma-
tion between ligand-activated receptors and Smad2 occurs
more rapidly, more pSmad2 complexes are accumulated in
the nucleus for a longer period, and the time to achieve
peak accumulation of nuclear pSmad2 is shortened some-
what. Conversely, the slower binding of Smad2 to the recep-
tors induces lower and slower accumulation of pSmad2 in
the nucleus. These results suggest that regulation of the
active state of the ligand-activated receptors and their
complex formation with R-Smads may significantly affect
the system responses to TGF-b through the nuclear retention
of pSmad2 complexes in terms of the intensity and the dura-
tion of transcriptional activity.
The effect of nuclear Smad complex formation
We also investigated how Smad complex formation in the
nucleus affects nuclear accumulation of activated Smad
complexes, by varying the rate of association between
nuclear pSmad2 and Smad4 (k18a) 10-fold (Fig. 6 B). The
results show that although rapid formation of the complex
between nuclear pSmad2 and Smad4 induces prolonged
and enhanced nuclear accumulation of pSmad2-Smad4
complex, slow binding of pSmad2 and Smad4 leads to short-
ened and attenuated retention of pSmad2 complex in the
nucleus. Thus, these results imply that the nuclear complex
formation step plays an important role in regulating the
Biophysical Journal 96(5) 1733–1750intensity and duration of TGF-b-targeted transcriptional
activities through pSmad2 complexes. More importantly,
the results imply that pSmad2 complex-mediated response
to TGF-b stimulation may be attenuated significantly by
competitive inhibition or by interference from other nuclear
molecules that also have high affinity for either pSmad2 or
Smad4. This inhibitory action ultimately gives rise to
a significant reduction in the rate of association between
these proteins. This conclusion is supported by a recent
finding that a ubiquitous nuclear protein, transcriptional
intermediary factor 1g (TIF1g), selectively binds receptor-
phosphorylated Smad2/3 in competition with Smad4
(54,55). There is also the possibility that other molecules
not yet identified may bind to either pSmad2 or Smad4
with high affinity; these putative molecules then would
hamper complex formation between pSmad2 and Smad4.
Taken together, these results show that the step of complex
formation between pSmad2 and Smad4 is associated closely
with modulation of TGF-b-induced signal patterns.
The effect of signal turn-off
Inactivation of ligand-activated R-Smads is crucial for
controlling the extent of TGF-b effects. In our model, irre-
versible inactivation and termination of the pSmad2-medi-
ated signals can be achieved in one of two ways: i), via
ligand-induced ubiquitination and subsequent degradation
by proteasomes; or ii), via dephosphorylation by inorganic
phosphatases. We examined the effect of ligand-induced
degradation of nuclear pSmad2 on the nuclear retention of
pSmad2 complexes by changing the rate constant (k20lid)
Modeling of TGF-b Signaling 174310-fold. Fig. 6 C shows that slower degradation of pSmad2
results in higher and more sustained activity of nuclear
pSmad2 complexes. On the other hand, when the rate of
degradation is increased, the activity of pSmad2 complexes
in the nucleus decreases more rapidly immediately after at-
taining its peak value, dropping almost to zero in the long
term, hence resulting in transient dynamics. Taken together
with the previous sensitivity analysis results, these simula-
tions show that ligand-induced multi-ubiquitination via
Smurf2 protein and subsequent degradation of activated
Smad2 by proteasomes can play a vital role in regulating
TGF-b-dependent transcription.
Similar system responses were obtained when the rates of
pSmad2 dephosphorylation (k8dp and k19dp) were changed
10-fold (Fig. 6 D). When pSmad2 dephosphorylation
occurred faster, the peak activity of nuclear pSmad2
complexes was noticeably reduced and the activity reached
steady state more rapidly. However, the results show that
variations in the dephosphorylation rates also changed the
intensity of the response, but did not significantly affect
the signal duration. This is because dephosphorylation by
phosphatases can affect only the activity of nuclear Smads,
and not the irreversible termination of the component itself.
In other words, even though nuclear pSmads lose their
activity by dephosphorylation, they can be rephosphorylated
after exiting the nucleus, as long as the receptor activated
signaling pathways remain active. These results therefore
indicate that ligand-induced ubiquitination and subsequent
proteasomal degradation can play an important role in regu-
lating both the duration and intensity of Smad-mediated
signal responses to TGF-b, whereas dephosphorylation
may have a significant effect only on the signal intensity.
The effect of inhibiting nuclear import of active
Smads
It has been reported that Smad activity can be regulated by
diverse extracellular signal inputs through corresponding
kinase pathways (2,6). One of the interactions between
Smad and other pathways is achieved by direct phosphoryla-
tion of the linker region connecting the MH1 and MH2
domains of Smad proteins. This region is phosphorylated
by endogenous mitogen-activated protein kinase, Ca2þ-
calmodulin-dependent protein kinase II, and cyclin-depen-
dent kinases. These inputs attenuate the nuclear accumula-
tion and transcriptional activity of Smads, and negatively
impact TGF-b signaling function. Although our model is
limited in its ability to investigate all possible effects of
crosstalk between TGF-b and other signaling pathways, still
we are able to examine the effect of such input signals on the
nuclear accumulation of Smads by directly varying the rate
of nuclear import of TGF-b-activated Smads. Fig. 6 E shows
that a large (10-fold) increase in the rates of nuclear translo-
cation of both monomeric and complexed pSmad2 (k7imp and
k17imp) does not have a pronounced effect on the nuclearretention of Smads. A 10-fold decrease in the rates resulted
in a reduced response, but its effect is relatively insignificant
when compared with the effects of variations in the param-
eter values of other important steps in the pathway. The
immediate implication is that nuclear retention of Smads is
relatively insensitive to crosstalk between Smad and other
kinase pathways through phosphorylation of the Smad linker
and consecutive inhibition of their entry to the nucleus.
TGF-b-dose-dependent responses
We examined the effect of various TGF-b concentrations
well within the measured physiological extremes that
surround cancer cells during cancer progression on the
dynamics of the signaling system. Step inputs of four
different concentrations of TGF-b (0.02, 0.2, 2, and
20 pM) were used to investigate the dose effects. These
concentrations represent the range of measured concentra-
tions of TGF-b produced by prostate cancer cells (0.4–
4.8 pM) or bone marrow stromal cells (2.5–7 pM), or
prostate fibroblasts (5 pM) (J. C. O’Connor and M. C.
Farach-Carson, unpublished). All other conditions, including
the initial conditions and kinetic parameters, remained the
same. Fig. 7 A shows that as the TGF-b concentration
increases, the activity of receptor complexes also increases
and the peak activity time increases somewhat. Increases in
TGF-b concentration also enhanced activity of receptor-acti-
vated Smad complexes and induced faster kinetics for active
Smad complexes by allowing Smads to reach peak activity
somewhat more rapidly (Fig. 7 B). For instance, although
0.02 pM of TGF-b induced maximum activity of Smads in
93 min, 20 pM of TGF-b resulted in peak activity of Smad
in 54 min. Considering that activated Smad complexes in
the nucleus regulate expression of TGF-b-target genes,
these results show that an increase in the concentration of
TGF-b may accelerate and enhance Smad-mediated cellular
responses.
It is important to note that as the TGF-b concentration
increases, the observed differences in the signaling activity
diminish. For example, the response to a 2 pM stimulus is not
significantly different from that for a 20 pM stimulus. This
observation is true for both receptors and Smads. These
results show that there is a saturation concentration of TGF-b
above which Smad-mediated signaling responses within a cell
no longer change. In other words, no matter how many bioac-
tive TGF-b molecules are available in the extracellular space,
each cell has a receptor-limited capacity to respond to them
and consequently induce the corresponding signal responses.
In-silico mutations
How can cancer cells become resistant to the tumor-
suppressor effects of TGF-b, but, at the same time, remain
responsive to the tumor-promoter effects? We believe that
differences between normal and cancerous signaling
responses could offer some clues.
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dynamic responses of (A) internalized activated receptor complex and (B)
activated Smad2-Smad4 complex in the nucleus under normal conditions,
and (C) internalized activated receptor complex and (D) activated Smad2-
Smad4 complex in the nucleus under cancerous conditions with 10-fold
Biophysical Journal 96(5) 1733–1750It is known that some signaling effectors of the TGF-b
pathway are abnormally altered in many human tumors
(56). Specifically, aberrant alterations such as mutations,
deletions, and downregulation of Type I and/or Type II
receptors are observed most frequently in a variety of human
cancers including prostate, breast, ovarian, bladder, gastric,
and pancreatic cancer. We have therefore investigated the
effect on the TGF-b signaling system of some of these
common abnormal alterations in receptors, using a 10-fold
reduction in the initial levels and production rate of both
Type I and Type II receptors to represent cancerous condi-
tions.
First, Fig. 7, C and D, show the TGF-b dose-dependent
responses for cancerous cells, corresponding to what was
shown earlier in Fig. 7, A and B, for normal cells. Although
a comparison of Fig. 7, A and C, shows only slight differ-
ences in the relative activity of receptor complexes for
normal and cancerous cells, the situation is different with
the nuclear Smad-mediated activity. Fig. 7 E indicates that
the amount of TGF-b needed to produce saturated Smad-
mediated response in cancer cells is far higher than that in
healthy cells. Specifically, whereas the response for normal
cells is essentially saturated with 0.1 pM of TGF-b (with
higher doses producing essentially the same response) at
least 1 pM of TGF-b is required before the Smad-mediated
response begins to approach saturation. This is, of course,
a direct effect of the reduction in the number of functional
receptors in cancer cells (56) that renders the them less
responsive to TGF-b stimulation. But this finding also indi-
cates an important characteristic of cancerous cells: to elicit
nuclear Smad-mediated activity generally requires more
TGF-b than normal.
Next, a head-to-head comparison of normal versus
cancerous cell responses shows some very interesting
features. Fig. 8 A shows that when the level of functional
receptors is very low, the activity of ligand-activated receptor
complexes (in response to a step of 2 ng/mL, or 80 pM TGF-
b) is significantly attenuated compared to that in the normal
system. Specifically, the peak level of active receptors in the
cancerous system plunges by an astounding 92%. Thus, even
though the dose-response characteristics of active receptors
are essentially similar for both classes of cells, the actual
peak level attained is significantly lower for cancer cells.
Once again, this is consistent with what one would expect
from cells having fewer functional receptors (56).
Not surprisingly, due to the correlation between active
receptors and nuclear pSmads, Fig. 8 B shows that the sharp
drop in the level of functional receptors in cancer cells leads
to a marked decrease in the activity of nuclear pSmad
reduction in initial levels and protein synthesis rate constants of both Type
I and Type II receptors. (E) Maximum responses of activated nuclear
Smad2-Smad4 complex to different doses of TGF-b (0.02, 0.1, 0.2, 1, 2,
10, and 20 pM) in normal cells (open circles) and cancerous cells (solid
triangles), respectively.
Modeling of TGF-b Signaling 1745FIGURE 8 In silico mutation results. Responses of (A) internalized acti-
vated receptor complex and (B) nuclear pSmad-Smad4 complex to 10-fold
reduction in initial levels and protein synthesis rate constants of both Type
I and Type II receptors. (C) Temporal profiles of phosphorylated Smad2
in HaCaT cells (circles, from Lo and Massague (43)), LNCaP cells (trian-complexes. Compared to the normal cell response, the peak
activity of nuclear pSmad complexes in cancer cells was
reduced by 65%, with the steady-state activity also remain-
ing comparatively low.
Interestingly, a reduction in the level of receptors also
slowed nuclear pSmad responses. Although nuclear pSmads
in the normal system reached maximum activity in 55 min,
their activity under a cancerous condition peaked at 86 min.
These results are consistent with our own experimental obser-
vations of Smad2 phosphorylation in some prostate cancer
cell lines (i.e., LNCaP and C4-2) as shown in Fig. 8 C.
(A separate assay, not shown, confirmed that both LNCaP
and C4-2 cells have low levels of TGF-b Type I and Type II
receptor proteins.) Whereas peak activity of phosphorylated
R-Smads is attained ~1 h after ligand addition in cells with
intact TGF-b signaling machinery (43), the metastatic pros-
tate cancer cells with reduced functional receptors showed
peak activity much later, as a result of the slower dynamics
of activated Smad2 (Fig. 8 C). Although the kinetics of
pSmad2 in the cancer cells could potentially be affected by
many factors (e.g., cancer types, cell lines, cell culture condi-
tions, etc.), our simulation and experimental results reveal that
reduction in the receptor levels, a notable phenotypic differ-
ence between normal and cancer cells, is associated closely
with differences in the dynamic behavior of the pathway.
Taken together, these results indicate generally that
a reduction in the level of functional TGF-b receptors in
cancer cells may lead to attenuated and slower TGF-b-stim-
ulated signaling responses via Smad2. The specific implica-
tions of the model predictions in Figs. 7 and 8 show some
potentially important findings about TGF-b and cancer
cells: i), cancer cells require higher than normal levels of
TGF-b to elicit significantly attenuated (and much slower)
nuclear Smad-mediated activity; and ii), even the increased
levels of TGF-b will never be able to produce Smad-medi-
ated responses that will be anywhere close to normal because
of the saturation effect shown in Fig. 7 D. These characteris-
tics may have significant implications for cancer therapies
that are based on targeting TGF-b.
Hypotheses on the dual role of TGF-b
As seen above, the dynamic patterns of major signaling
components in cancer cells in response to TGF-b may be
quite different from those in normal cells. Such differences
may provide clues regarding the role of TGF-b—tumor
suppressor or tumor enhancer—during cancer progression.
Here, we postulate four testable nonmutually exclusive
gles, our experiments), and C4-2 cells (squares, our experiments) in
response to 200 pM (for A) or 400 pM (for B and C) of TGF-b. The open
triangles and squares represent the maximum and minimum of the data at
each time point; the solid squares and triangles denote the corresponding
average values. All data points were normalized with respect to the
maximum intensity value of pSmad2 of each profile.
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Hypothesis 1: different thresholds for gene expression
As shown above via simulation, cancer cells have attenuated
TGF-b-stimulated Smad pathway responses. Such cells have
been confirmed experimentally to be resistant to the antipro-
liferative effect of TGF-b, while showing typical proonco-
genic responses. Such behavior may be explained in part
by the following ‘‘threshold hypothesis’’: in response to
TGF-b, growth-inhibitory genes require higher threshold
levels of nuclear Smad activity for their expression than
genes associated with prooncogenic and prometastatic
effects. In other words, under normal conditions, or in the
early stage of cancer progression, the antiproliferative
responses to TGF-b are predominant over prooncogenic
responses. This is because the transcriptional activity of
nuclear pSmad is high enough to induce anti-growth gene
expression. However, as cancer progresses, this transcrip-
tional activity may decline significantly and thereby hardly
exceed the threshold necessary for the expression of
growth-inhibition genes. Meanwhile, genes related to
tumor-promoting effects may be relatively insensitive to
the attenuation of the transcriptional activity by Smads, so
that the expression of such genes remains approximately
unchanged even under cancerous conditions. As a conse-
quence, the dominance of tumor suppressor genes over the
tumor-promoter genes may be blunted in cancer cells. This
hypothesis is supported in part by previous experimental
observations that cells with reduced TGF-b receptor function
showed resistance to the antiproliferative effect of TGF-b,
whereas other TGF-b responses were not significantly
affected (51,57–59). We believe that further investigation
into differences in the temporal profiles of gene expression
and thresholds of anti-growth and prooncogenic genes
induced by TGF-b will provide some clues regarding the
putative dual effects of TGF-b.
Hypothesis 2: fast degradation of signaling components
It has been suggested that the duration of TGF-b/Smad
signaling is a critical determinant for regulating specificity
of cellular responses (60). For example, Nicolas and Hill
(51) reported that normal epithelial cells (HaCaT and
Colo-357) with sustained retention of active Smad in the
nucleus (>6 h after TGF-b addition) are sensitive to growth
inhibition by TGF-b. In contrast, pancreatic cancer cells
(PT45 and Panc-1) showing transient nuclear retention of
active Smads (1–2 h after TGF-b treatment) preferentially
evade the growth-inhibitory effects of TGF-b, with no
changes to other responses. Thus, it seems likely that the
expression profile of TGF-b-inducible genes required for
cell cycle arrest may differ depending on the dynamic
patterns of nuclear pSmads. Taking into account that such
pancreatic cancer cell lines contain low levels of TGF-b
Type I receptor protein (51), one may be tempted to conclude
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the transient accumulation of pSmads in the nucleus to
induce alteration in the expression profiles of the anti-growth
genes. However, reduced levels of receptors may not be the
only factor leading to the experimentally observed short-
term signal response to TGF-b. We hypothesize that such
transient dynamic behavior of nuclear pSmads results from
not only a reduction in receptor levels but also from other
mechanisms, especially mechanisms associated with rapid
degradation of major signaling components in the pathway.
We have already seen responses become transient when
the rate of pSmad2 degradation increased (Fig. 6 C). Alter-
ations in the mechanism(s) involved in degradation of
pSmad2 during cancer progression may therefore account
for producing transient signal responses to TGF- b.
It also is possible that Smad4 may be a major target for
rapid degradation. Western blot analysis (51) showed that
whereas the activity of Smad4 is sustained in normal cells
during active signaling, Smad4 from nuclear extracts of
pancreatic cancer cells shows fairly transient dynamics.
We suspect that the transient dynamics of Smad4 in cancer
cells result from an expedited degradation process for
Smad4 (Fig. 9 A). To confirm that such a rapid degradation
of these two major signaling components, pSmad2 and
Smad4, contributes to the transient dynamics of nuclear
pSmad2 under cancerous conditions, we carried out simula-
tions with 10-fold increases in the rate constants for either
pSmad2 or Smad4 or both under cancerous conditions where
the level of receptors is reduced 10-fold. Fig. 9 B shows that
the increased degradation rate of pSmad2 and/or of Smad4,
along with decreased expression of receptors, leads to
more attenuated and transient dynamics of activated Smads,
compared to the response to a decrease in the level of the
receptors alone. This hypothesis is corroborated by previous
findings that in response to TGF-b, tumor cells show
increased production of proteases and downregulation of
the protease inhibitors, leading to rapid degradation of
signaling components; these features are not observed in
normal cells (61). Further investigations into changes in
the degradation mechanisms of the signaling components
in the pathway during cancer progression may therefore be
important in understanding the apparently contradictory
roles of TGF-b.
Hypothesis 3: competitive inhibition by nuclear binding
partner of pSmad
Our sensitivity analysis has shown that association and
dissociation between pSmad2 and Smad4 in the nucleus
critically affect nuclear accumulation of pSmad2-Smad4
complexes in terms of signal intensity and duration. In
particular, Fig. 6 B shows that retardation of nuclear complex
formation of pSmad2 with Smad4 leads to attenuated and
transient signal responses. We hypothesize that one possible
factor in the sluggishness of pSmad2-Smad4 complex forma-
tion is competitive inhibition by other binding partners of
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This is supported by a recent finding that a ubiquitous
nuclear protein, TIF1g, can selectively bind to ligand-acti-
vated Smad2/3, competing with Smad4 (54), a schematic
diagram of which is shown in Fig. 10. This study suggests
the possible existence of hitherto unidentified binding part-
ners that show high affinity for receptor-phosphorylated
Smad2.
Such binding partners may inhibit not only complex
formation between pSmad2 and Smad4, but also may
mediate cellular responses different from those mediated
by Smad4. The same study (54) showed that in human
hematopoietic progenitor cells, the binding of receptor-phos-
phorylated Smad2/3 to Smad4 mediates inhibition of prolif-
eration, whereas complex formation of pSmad2/3 with
FIGURE 9 Model predictions for (A) nuclear Smad4 and (B) nuclear
pSmad2-Smad4 complex on TGF-b stimulation (80 pM) under cancerous
conditions; 10-fold reduction in the initial levels and the protein synthesis
rate constants of both Type I and Type II receptors, and 10-fold increase
in rates of degradation of either Smad4 (A, squares; B, diamonds) or pSmad2
(B, triangles) or both (B, squares).TIF1g mediates differentiation in response to TGF-b. This
result strongly suggests the possibility that the Smad
pathway can mediate a variety of cellular responses through
its branch pathways, depending on nuclear binding partners
of TGF-b-induced R-Smads. In particular, if such putative
binding partners can mediate cellular responses contradic-
tory to those mediated by Smad4, this may explain the
dual role of TGF-b during cancer progression. Suppose
that during cancer progression the rate of complex formation
between R-Smads and Smad4 slows because of either lower
affinity between those molecules or because of higher
affinity between R-Smads and other binding proteins, due
to conformational changes by mutations or for other reasons.
Suppose as well that such binding proteins strongly mediate
tumor-promoting responses such as EMT, invasion, and
survival. A decreased rate of complex formation between
pSmads and Smad4 in the nucleus can lead to an increased
number of free nuclear pSmads that can bind to other nuclear
partners; this makes for a higher probability of complex
formation between pSmads and other partners. Considering
that slow association of pSmad2 with Smad4 leads to atten-
uated and transient responses (primarily tumor-suppressive
ones), increased complex formation between pSmad2 and
potential binding factors may cause higher and prolonged
tumor-promoting responses. Consequently, in cancers, an
imbalance between tumor-suppressing responses by Smad4
and tumor-promoting responses by potential binding factors
may explain the paradox of TGF-b.
FIGURE 10 Alternative TGF-b-induced responses determined by nuclear
pSmad2-binding partners. Whereas Smad4 forms transcriptional complexes
with receptor-phosphorylated Smad2/3 and mediates antiproliferative
responses, TIF1g specifically recognizes receptor-activated Smad2/3 and
mediates differentiation of hematopoietic stem/progenitor cells. (Adapted
from He et al. (54)).
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Although the aforementioned hypotheses deal with potential
intracellular mechanisms by which the tumor suppressor
effects of TGF-b are lessened in cancer, the question remains
why the levels of TGF-b are unusually high in the primary
tumor and plasma of cancer patients with poor prognosis,
given that this cytokine is primarily a tumor suppressor/
growth inhibitor? The observed correlation between high
levels of TGF-b and poor prognosis has often led many
researchers to reach a consensus that the elevated TGF-b level
is an indication that TGF-b is a tumor promoter; accordingly,
significant efforts have been devoted to developing TGF-
b inhibitors as cancer therapy (62).
However, our dose-response results provide a potential
alternative perspective of this clinical observation, i.e., that
increased levels of TGF-b correlate with poor prognosis
does not mean that the former causes the latter. First, the simu-
lations results in Fig. 7 show that cancer cells may require
higher than normal levels of TGF-b to elicit nuclear Smad-
mediated activity. If nuclear Smad-mediated activity is neces-
sary for effective tumor suppression/growth inhibition, then
this result is consistent with the established fact that, as a result
of loss of functional TGF-b receptors, cancer cells become
resistant to the growth inhibitory effect of TGF-b (63).
Now, from a control theory perspective, this phenomenon
seems to be analogous to that of a temperature control
problem in an exothermic nuclear reactor supplied with a cool-
ing jacket. If the cooling jacket surrounding the reactor
becomes encrusted with accumulated deposits from the water
supply, the reactor will become less responsive to the cooling
water, and increasing amounts will be needed to cool the
reactor. As the reactor walls become even less responsive
with time, an automatic temperature controller will call for
increasing amounts of cooling water even as the temperature
continues to rise; the rising temperature will cause more
nuclear reaction, which in turn will cause the temperature to
rise even further. Eventually meltdown will occur when the
cooling is no longer able to keep up. A postaccident analysis
of these circumstances will show the increasing temperature
accompanied by increasing cooling water flow rate, giving
the illusion that the cooling water caused the temperature to
increase. However, common sense will dismiss this as invalid
because the role of cooling water in reactor temperature
control is well understood.
We therefore hypothesize that there exists a cellular control
system that uses the tumor suppressor ligand, TGF-b, to
achieve its objective of regulating cell growth (64). This
control system functions effectively in normal cells because
they are responsive to this ligand. But as a direct consequence
of TGF-b resistance in tumor cells, the still-intact control
system must now secrete more of this ligand in a futile attempt
to achieve the level of tumor suppression attainable with
normal, responsive cells. Thus, the observed increased level
of TGF-b is a consequence of this acquired TGF-b resistance
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between increased levels of TGF-b and poor prognosis has
been inadvertently misconstrued as causality, creating the
apparent paradox. The clinically observed increased TGF-b
level is therefore not an indication that the tumor suppressor
role of TGF-b has changed fundamentally; rather, with this
control system hypothesis, it is consistent with TGF-b’s
role as a tumor suppressor that its level should increase in
an attempt to elicit normal responses from a tumor that is
becoming increasingly resistant to the cytokine.
If this hypothesis is true, the consequences for how TGF-b
ligand and TGF-b receptors are used as therapeutic agents will
be significant. Specifically, it will mean that the current
approach of targeting TGF-b ligand therapeutically may
have to be abandoned in favor of re-sensitizing the cells to
the tumor suppressive effect of the TGF-b, similar to treat-
ment for diabetes mediated by prolonged insulin-resistance
(65).
We intend to investigate and test each of these hypotheses
in subsequent studies.
CONCLUSIONS
In this work we have presented a mathematical description of
the TGF-b signaling pathway that is more comprehensive
and more realistic than the previous computational models;
it integrates extracellular signal transduction and intracellular
signal transmission, and includes some reaction mechanisms
modified from previous models to be better aligned with
current knowledge of the TGF-b pathway. The model, which
shows good fit to multiple sources of experimental data,
simultaneously, was also validated against several totally
different, independent sets of data from different sources,
without adjusting any model parameters. Extensive analysis
of the model (parametric sensitivity and model predictions
under various physiological conditions) has provided insight
into basic characteristics of the TGF-b signaling system.
We believe that our model also yields new insights into the
relationship between ligand stimulation and corresponding
responses via binding of TGF-b to its receptor at the cell
surface and the activation of downstream effectors in the
signaling cascade; it also yields new insights into molecular
TGF-b-induced response characteristics that distinguish
between normal and cancer cells. Furthermore, these results
provide some clues that may be helpful in unraveling long-
standing questions about the seemingly contradictory roles
of TGF-b during cancer progression. However, the model
still has some limitations. We plan to expand the current
model first to incorporate the effect of crosstalk among other
important signaling cascades, and later gene expression
mechanisms. Our future plans also include focusing on pros-
tate cancer (PCa), customizing this computational model for
the PCa cell lines of the LNCaP human prostate cancer
progression model available in our laboratory, and using
the models for a model-guided experimental study of the
Modeling of TGF-b Signaling 1749role of TGF-b during PCa progression and testing the four
hypotheses postulated above.
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